Exelixis, Inc. (EXEL)
USD 33.68
(-2.57%)
USD 33.68
(-2.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 196.6 Million USD | -2.42% |
| 2022 | 222.35 Million USD | -29.71% |
| 2021 | 300.29 Million USD | 160.46% |
| 2020 | 110.06 Million USD | -70.21% |
| 2019 | 369.47 Million USD | -18.28% |
| 2018 | 438.85 Million USD | 170.35% |
| 2017 | 168.29 Million USD | 848.31% |
| 2016 | -36.16 Million USD | 81.37% |
| 2015 | -119.6 Million USD | 43.55% |
| 2014 | -217.72 Million USD | -7.18% |
| 2013 | -196.36 Million USD | -87.83% |
| 2012 | -114.73 Million USD | -204.38% |
| 2011 | 100.07 Million USD | 310.82% |
| 2010 | -72.51 Million USD | 60.16% |
| 2009 | -115.57 Million USD | 28.95% |
| 2008 | -155.58 Million USD | 22.83% |
| 2007 | -157.04 Million USD | -99.91% |
| 2006 | -109.84 Million USD | -44.09% |
| 2005 | -70.86 Million USD | -25.98% |
| 2004 | -89.05 Million USD | 21.68% |
| 2003 | -77.58 Million USD | -10.43% |
| 2002 | -70.41 Million USD | -58.76% |
| 2001 | -53.43 Million USD | -412.83% |
| 2000 | -24 Million USD | 207.53% |
| 1999 | -13.1 Million USD | 14.36% |
| 1998 | -15.29 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 136.07 Million USD | -31.16% |
| 2024 Q1 | 101.51 Million USD | -22.24% |
| 2024 Q2 | 283.67 Million USD | 313.07% |
| 2023 Q3 | -17.58 Million USD | -122.59% |
| 2023 Q4 | 88.31 Million USD | 602.27% |
| 2023 Q1 | 28.83 Million USD | 159.97% |
| 2023 Q2 | 77.85 Million USD | 170.03% |
| 2023 FY | - USD | -2.42% |
| 2022 Q1 | 83.24 Million USD | -28.63% |
| 2022 Q4 | -48.07 Million USD | -154.46% |
| 2022 Q3 | 88.27 Million USD | -0.23% |
| 2022 FY | - USD | -29.71% |
| 2022 Q2 | 88.48 Million USD | 6.29% |
| 2021 Q4 | 116.64 Million USD | 106.72% |
| 2021 FY | - USD | 160.46% |
| 2021 Q1 | -1.38 Million USD | -105.68% |
| 2021 Q2 | 126.67 Million USD | 9279.42% |
| 2021 Q3 | 56.42 Million USD | -55.46% |
| 2020 Q2 | 77.73 Million USD | 41.38% |
| 2020 FY | - USD | -70.21% |
| 2020 Q3 | -40.22 Million USD | -151.75% |
| 2020 Q4 | 24.29 Million USD | 160.4% |
| 2020 Q1 | 54.98 Million USD | -28.88% |
| 2019 FY | - USD | -18.28% |
| 2019 Q2 | 94.68 Million USD | 11.97% |
| 2019 Q1 | 84.55 Million USD | -27.34% |
| 2019 Q4 | 77.31 Million USD | -34.7% |
| 2019 Q3 | 118.4 Million USD | 25.05% |
| 2018 Q2 | 89.2 Million USD | -24.64% |
| 2018 FY | - USD | 170.35% |
| 2018 Q1 | 118.37 Million USD | 204.15% |
| 2018 Q3 | 130.65 Million USD | 46.47% |
| 2018 Q4 | 116.37 Million USD | -10.93% |
| 2017 Q2 | 28.95 Million USD | 34.29% |
| 2017 Q3 | 84.86 Million USD | 193.08% |
| 2017 FY | - USD | 848.31% |
| 2017 Q1 | 21.56 Million USD | -45.79% |
| 2017 Q4 | 38.91 Million USD | -54.14% |
| 2016 Q2 | -23.13 Million USD | 52.4% |
| 2016 FY | - USD | 81.37% |
| 2016 Q3 | 10.37 Million USD | 144.85% |
| 2016 Q4 | 39.77 Million USD | 283.34% |
| 2016 Q1 | -48.61 Million USD | -54.64% |
| 2015 FY | - USD | 43.55% |
| 2015 Q4 | -31.43 Million USD | 9.79% |
| 2015 Q3 | -34.84 Million USD | -17.71% |
| 2015 Q2 | -29.6 Million USD | -29.3% |
| 2015 Q1 | -22.89 Million USD | 45.74% |
| 2014 Q2 | -60.4 Million USD | 3.07% |
| 2014 Q3 | -44.59 Million USD | 26.16% |
| 2014 Q1 | -62.31 Million USD | -5.88% |
| 2014 Q4 | -42.19 Million USD | 5.4% |
| 2014 FY | - USD | -7.18% |
| 2013 Q1 | -32.71 Million USD | -3.21% |
| 2013 FY | - USD | -87.83% |
| 2013 Q2 | -49.52 Million USD | -51.41% |
| 2013 Q4 | -58.85 Million USD | -5.94% |
| 2013 Q3 | -55.55 Million USD | -12.18% |
| 2012 Q3 | -22.96 Million USD | 22.98% |
| 2012 Q4 | -31.69 Million USD | -38.03% |
| 2012 Q2 | -29.81 Million USD | -41.29% |
| 2012 Q1 | -21.09 Million USD | -136.83% |
| 2012 FY | - USD | -204.38% |
| 2011 FY | - USD | 310.82% |
| 2011 Q1 | -12.26 Million USD | -156.42% |
| 2011 Q2 | -19.03 Million USD | -55.18% |
| 2011 Q3 | 83.84 Million USD | 540.43% |
| 2011 Q4 | 57.29 Million USD | -31.67% |
| 2010 Q2 | -13.01 Million USD | 22.28% |
| 2010 Q4 | -4.78 Million USD | -227.0% |
| 2010 FY | - USD | 60.16% |
| 2010 Q1 | -16.75 Million USD | 38.04% |
| 2010 Q3 | -1.46 Million USD | 88.76% |
| 2009 Q1 | -33.48 Million USD | 3.65% |
| 2009 Q4 | -27.03 Million USD | -64.2% |
| 2009 Q3 | -16.46 Million USD | 52.27% |
| 2009 Q2 | -34.49 Million USD | -2.99% |
| 2009 FY | - USD | 28.95% |
| 2008 Q3 | -45.84 Million USD | -1.0% |
| 2008 Q2 | -45.38 Million USD | -4.45% |
| 2008 FY | - USD | 22.83% |
| 2008 Q1 | -43.45 Million USD | 42.72% |
| 2008 Q4 | -34.75 Million USD | 24.18% |
| 2007 Q1 | -30.52 Million USD | -1.32% |
| 2007 Q2 | -35.84 Million USD | -17.42% |
| 2007 Q3 | -77.34 Million USD | -115.77% |
| 2007 FY | - USD | -99.91% |
| 2007 Q4 | -75.86 Million USD | 1.91% |
| 2006 FY | - USD | -44.09% |
| 2006 Q1 | -26.47 Million USD | -6.27% |
| 2006 Q2 | -25.75 Million USD | 2.75% |
| 2006 Q3 | -27.45 Million USD | -6.62% |
| 2006 Q4 | -30.13 Million USD | -9.75% |
| 2005 Q3 | -23.32 Million USD | -339.39% |
| 2005 FY | - USD | -25.98% |
| 2005 Q2 | -5.3 Million USD | 76.6% |
| 2005 Q1 | -22.68 Million USD | -471.64% |
| 2005 Q4 | -24.91 Million USD | -6.83% |
| 2004 Q4 | 6.1 Million USD | 127.12% |
| 2004 FY | - USD | 21.68% |
| 2004 Q1 | -22.97 Million USD | -30.08% |
| 2004 Q3 | -22.5 Million USD | -10.69% |
| 2004 Q2 | -20.33 Million USD | 11.5% |
| 2003 Q1 | -19.17 Million USD | -41.49% |
| 2003 Q2 | -20.11 Million USD | -9.03% |
| 2003 Q3 | -20.17 Million USD | 7.22% |
| 2003 FY | - USD | -10.43% |
| 2003 Q4 | -18.12 Million USD | 9.11% |
| 2002 Q3 | -19.31 Million USD | 5.36% |
| 2002 Q1 | -15.25 Million USD | -7.5% |
| 2002 Q2 | -20.29 Million USD | -29.66% |
| 2002 FY | - USD | -58.76% |
| 2002 Q4 | -14.2 Million USD | 29.68% |
| 2001 Q2 | -12.02 Million USD | 44.9% |
| 2001 Q3 | -11.47 Million USD | -114.3% |
| 2001 Q4 | -17.32 Million USD | -27.53% |
| 2001 FY | - USD | -412.83% |
| 2001 Q1 | -9.72 Million USD | -19.19% |
| 2000 FY | - USD | 207.53% |
| 2000 Q2 | -6.41 Million USD | -98.45% |
| 2000 Q3 | -6.2 Million USD | 3.14% |
| 2000 Q1 | -3.23 Million USD | 0.0% |
| 2000 Q4 | -8.15 Million USD | -31.36% |
| 1999 FY | - USD | 14.36% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 202.313% |
| Alkermes plc | 495.04 Million USD | 60.286% |
| Agenus Inc. | -145.92 Million USD | 234.729% |
| Aptorum Group Limited | -9.59 Million USD | 2148.151% |
| Ardelyx, Inc. | -55.35 Million USD | 455.172% |
| Dyadic International, Inc. | -8.22 Million USD | 2488.921% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 67660.825% |
| Lantern Pharma Inc. | -15.78 Million USD | 1345.366% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 1087.335% |
| Novavax, Inc. | -487.39 Million USD | 140.338% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 376.811% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 350.471% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 1193.847% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 2072.331% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 442.656% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 151.742% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 915.373% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -37064.839% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 225.069% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 362.785% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1075.257% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 928.321% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 952.641% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 261.013% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 176.131% |
| AlloVir, Inc. | -190.14 Million USD | 203.395% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 211.914% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 771.96% |
| Bicycle Therapeutics plc | -183.4 Million USD | 207.198% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 218.849% |
| ChromaDex Corporation | -3.89 Million USD | 5148.844% |
| Chimerix, Inc. | -92.97 Million USD | 311.459% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 542.432% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 274.705% |
| CRISPR Therapeutics AG | -202.7 Million USD | 196.991% |
| Precision BioSciences, Inc. | -32.04 Million USD | 713.576% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 214.152% |
| Fortress Biotech, Inc. | -133.64 Million USD | 247.11% |
| Fortress Biotech, Inc. | -133.64 Million USD | 247.11% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 354.195% |
| ImmuCell Corporation | -2.5 Million USD | 7951.276% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 250.744% |
| Immix Biopharma, Inc. | -16.13 Million USD | 1318.433% |
| Incyte Corporation | 919.42 Million USD | 78.617% |
| Innoviva, Inc. | 248.96 Million USD | 21.031% |
| IO Biotech, Inc. | -91.22 Million USD | 315.506% |
| Jaguar Health, Inc. | -33.13 Million USD | 693.408% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 229.193% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -93.264% |
| ContextLogic Inc. | -324 Million USD | 160.68% |
| MiMedx Group, Inc. | 40.51 Million USD | -385.233% |
| MEI Pharma, Inc. | 26.38 Million USD | -645.269% |
| NextCure, Inc. | -59.03 Million USD | 433.004% |
| Onconetix, Inc. | -36.7 Million USD | 635.602% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -8696.51% |
| Opthea Limited | -200.01 Million USD | 198.292% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 7245.058% |
| Vaxcyte, Inc. | -464.88 Million USD | 142.29% |
| PDS Biotechnology Corporation | -40.08 Million USD | 590.463% |
| Precigen, Inc. | -89.22 Million USD | 320.342% |
| Pharming Group N.V. | 9.87 Million USD | -1890.503% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 223.611% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 963.729% |
| PureTech Health plc | -11.62 Million USD | 1790.909% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 1257.776% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 184.199% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 915.373% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 324.876% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 778.804% |
| Acelyrin, Inc. | -381.52 Million USD | 151.53% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 1525933.748% |
| Summit Therapeutics Inc. | 1 Million USD | -19540.559% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 688.876% |
| Senti Biosciences, Inc. | -61.33 Million USD | 420.533% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 275.062% |
| Elevation Oncology, Inc. | -41.46 Million USD | 574.117% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 736.17% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 3314.265% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 61346.729% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 705.805% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 2441.615% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 434.414% |
| Seer, Inc. | -97.88 Million USD | 300.85% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 416.096% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 400.776% |
| ESSA Pharma Inc. | -26.45 Million USD | 843.148% |
| GlycoMimetics, Inc. | -39.12 Million USD | 602.536% |
| GT Biopharma, Inc. | 5.97 Million USD | -3188.209% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 195.118% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 2962.58% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -126.469% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 446.411% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 483.846% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 2088.509% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 136.413% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 2955.927% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 519.534% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 183.087% |
| Aptose Biosciences Inc. | -52.26 Million USD | 476.142% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 282.472% |
| Soligenix, Inc. | -7.85 Million USD | 2603.575% |
| Century Therapeutics, Inc. | -121.2 Million USD | 262.202% |
| Kura Oncology, Inc. | -164.95 Million USD | 219.185% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 345.452% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 2049.256% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 20627.722% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 4662.59% |
| Autolus Therapeutics plc | -156.77 Million USD | 225.408% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 332.234% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 384.926% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 1086.265% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 203.872% |
| GRI Bio, Inc. | -10.89 Million USD | 1904.019% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 4453.729% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 260.484% |
| IGM Biosciences, Inc. | -253.35 Million USD | 177.598% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 289.419% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 615.566% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 1382.39% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 1348.803% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 445.856% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 283.563% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 173.911% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 201.373% |
| Verastem, Inc. | -83.16 Million USD | 336.397% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 488.757% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 224.252% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 272.323% |
| Histogen Inc. | -10.5 Million USD | 1971.865% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 1476.793% |
| Surrozen, Inc. | -41.13 Million USD | 577.99% |
| Organovo Holdings, Inc. | -14.8 Million USD | 1427.854% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -6130302.245% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 434.852% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 483.285% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 1012.772% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 2457.902% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 218.388% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 499.123% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 913.548% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 1405.888% |
| Apollomics, Inc. | -171.74 Million USD | 214.472% |
| Amarin Corporation plc | -50.9 Million USD | 486.24% |
| Mesoblast Limited | -61.33 Million USD | 420.559% |
| Turnstone Biologics Corp. | -56.23 Million USD | 449.614% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 237.291% |
| Synaptogenix, Inc. | -8.3 Million USD | 2466.558% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 1381.713% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 411.834% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 4203.17% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -45723.806% |
| Better Therapeutics, Inc. | -38.26 Million USD | 613.831% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 239.031% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 139.701% |
| NLS Pharmaceutics AG | -11.79 Million USD | 1766.732% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -79426.406% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 766.312% |
| Gritstone bio, Inc. | -126.86 Million USD | 254.972% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 402.534% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 5015.116% |
| Avid Bioservices, Inc. | -11.48 Million USD | 1812.412% |
| Insmed Incorporated | -654.73 Million USD | 130.028% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 8838.958% |
| MediWound Ltd. | -4.89 Million USD | 4118.026% |
| OmniAb, Inc. | -49.73 Million USD | 495.331% |
| Alector, Inc. | -142.89 Million USD | 237.588% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 330.121% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 477.008% |
| Zai Lab Limited | -366.57 Million USD | 153.632% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 167.645% |
| Aura Biosciences, Inc. | -83.69 Million USD | 334.9% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 187.282% |
| Immunic, Inc. | -99.11 Million USD | 298.363% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 249.314% |
| Veracyte, Inc. | -49.4 Million USD | 497.907% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 2883.181% |
| FibroGen, Inc. | -261.4 Million USD | 175.21% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1864.671% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 2908.067% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 1150.4% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 86.436% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 873.354% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -392.86% |
| TG Therapeutics, Inc. | 26.1 Million USD | -653.264% |
| Galecto, Inc. | -37.51 Million USD | 624.007% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 613.791% |
| Fortrea Holdings Inc. | 167.3 Million USD | -17.515% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 246.412% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 794.437% |
| XBiotech Inc. | -35.76 Million USD | 649.69% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 402.534% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 401.306% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 288.217% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 865.823% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 581.078% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 138.068% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 450.943% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 350855.562% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 268.996% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 986.811% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 183.638% |
| NexImmune, Inc. | -28.16 Million USD | 797.974% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 3658.054% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 1767.211% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 95.776% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 874.267% |
| Scopus BioPharma Inc. | -11.71 Million USD | 1778.473% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 256.224% |
| Ainos, Inc. | -8.77 Million USD | 2340.964% |
| Pluri Inc. | -20.22 Million USD | 1072.074% |
| Prothena Corporation plc | -190.1 Million USD | 203.416% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 253.358% |
| Celularity Inc. | -183.94 Million USD | 206.88% |
| Rallybio Corporation | -72.37 Million USD | 371.651% |
| Cue Biopharma, Inc. | -46.05 Million USD | 526.913% |
| MeiraGTx Holdings plc | -57.05 Million USD | 444.601% |
| Omeros Corporation | -163.61 Million USD | 220.165% |
| Humacyte, Inc. | -96.45 Million USD | 303.821% |
| Immunocore Holdings plc | -59.64 Million USD | 429.598% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 1114.877% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 906.903% |
| Blueprint Medicines Corporation | -474.61 Million USD | 141.424% |
| CalciMedica, Inc. | -34.18 Million USD | 675.045% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 368.457% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 256.659% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 216.712% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 177.896% |
| Pulmatrix, Inc. | -12.64 Million USD | 1654.658% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 696.378% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 322.232% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 138.83% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 294.242% |
| Cytokinetics, Incorporated | -456.68 Million USD | 143.05% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 689.105% |
| Nutriband Inc. | -5.12 Million USD | 3938.551% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 554.34% |
| Vor Biopharma Inc. | -114.37 Million USD | 271.898% |
| Roivant Sciences Ltd. | -996.51 Million USD | 119.729% |
| Evogene Ltd. | -23.2 Million USD | 947.276% |
| ProKidney Corp. | -147.66 Million USD | 233.137% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 404.644% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 128473.022% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 134.768% |
| CorMedix Inc. | -48.88 Million USD | 502.156% |
| BioLineRx Ltd. | -57.06 Million USD | 444.547% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 275.918% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 97427.723% |
| Atai Life Sciences N.V. | -36.31 Million USD | 641.439% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 347.245% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 341.784% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 171.361% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 739.564% |
| MediciNova, Inc. | -9.87 Million USD | 2089.905% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 256.106% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 12948.116% |
| GeoVax Labs, Inc. | -26.66 Million USD | 837.199% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 187.382% |
| Biomea Fusion, Inc. | -124.62 Million USD | 257.761% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 159.515% |
| Mereo BioPharma Group plc | -26.05 Million USD | 854.536% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 203.29% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 185.501% |
| Absci Corporation | -95.45 Million USD | 305.959% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 754.794% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 283.538% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 184.207% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 960.214% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 194.595% |
| Allakos Inc. | -189.91 Million USD | 203.521% |
| Imunon, Inc. | -19.87 Million USD | 1089.029% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 281.213% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -81.494% |
| BioAtla, Inc. | -122.24 Million USD | 260.831% |
| NLS Pharmaceutics AG | -11.79 Million USD | 1766.732% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 1347.395% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 165.47% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 574.346% |
| XOMA Corporation | -39.36 Million USD | 599.472% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 298.08% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 267.108% |
| aTyr Pharma, Inc. | -52.17 Million USD | 476.791% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 334.567% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 232.275% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 183.816% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 1539.991% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 2544.599% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1270.111% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -104084.287% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 56.499% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 3177.376% |
| UroGen Pharma Ltd. | -63.83 Million USD | 408.004% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 389.482% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 2806.894% |
| Orgenesis Inc. | -60.71 Million USD | 423.795% |
| Entera Bio Ltd. | -8.8 Million USD | 2333.099% |
| GH Research PLC | -41.15 Million USD | 577.734% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 870.414% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 339.079% |
| Xencor, Inc. | -125.87 Million USD | 256.19% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 13881.689% |
| Replimune Group, Inc. | -230.19 Million USD | 185.406% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 1075.324% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 1896.765% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 3177.376% |
| Portage Biotech Inc. | -18.19 Million USD | 1180.29% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 12948.116% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 287.985% |
| OncoCyte Corporation | -23.12 Million USD | 950.244% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 1839.785% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 1816.023% |
| Purple Biotech Ltd. | -22.22 Million USD | 984.598% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 3167.114% |
| scPharmaceuticals Inc. | -46.06 Million USD | 526.83% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 1203.905% |
| HilleVax, Inc. | -132.46 Million USD | 248.417% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 1948.98% |
| Tharimmune, Inc. | -9.3 Million USD | 2213.412% |
| Genprex, Inc. | -31.06 Million USD | 732.963% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 204.84% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 727.04% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 25833.246% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -130182.829% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1248694.076% |
| Savara Inc. | -59.13 Million USD | 432.474% |
| Curis, Inc. | -45.13 Million USD | 535.548% |
| Daré Bioscience, Inc. | -30.7 Million USD | 740.366% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 1394.188% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 2843.922% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 835.401% |
| BeiGene, Ltd. | -1.12 Billion USD | 117.482% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 1306.058% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 145.66% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 317.625% |
| Erasca, Inc. | -121.31 Million USD | 262.066% |
| bluebird bio, Inc. | -167.16 Million USD | 217.612% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 4470.141% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 36.638% |
| DBV Technologies S.A. | -85.98 Million USD | 328.655% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 4470.141% |
| Moderna, Inc. | -3.28 Billion USD | 105.988% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 561.41% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 3580.914% |
| Molecular Templates, Inc. | 1.43 Million USD | -13648.392% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 428.48% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 160.262% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 243.412% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 515.07% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 241.406% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 195.503% |
| MacroGenics, Inc. | 2.01 Million USD | -9647.248% |
| RenovoRx, Inc. | -11.39 Million USD | 1826.093% |
| Adicet Bio, Inc. | -136.53 Million USD | 243.994% |
| Prime Medicine, Inc. | -193.75 Million USD | 201.467% |
| Aditxt, Inc. | -25.45 Million USD | 872.261% |
| Adagene Inc. | -14.95 Million USD | 1414.994% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2789.458% |
| Quantum-Si incorporated | -91.8 Million USD | 314.154% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 72.403% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -55.472% |
| SciSparc Ltd. | -5.28 Million USD | 3822.113% |
| Vericel Corporation | 2.86 Million USD | -6764.595% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 206597.353% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 1006.358% |
| Generation Bio Co. | -133.3 Million USD | 247.488% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 336.784% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 328.546% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 186.444% |
| Invivyd, Inc. | -196.61 Million USD | 199.993% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 152.546% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 2219.744% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -624.026% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 2011.541% |
| 2seventy bio, Inc. | -206.41 Million USD | 195.245% |
| ADMA Biologics, Inc. | 5.12 Million USD | -3739.883% |
| Clene Inc. | -43.24 Million USD | 554.666% |
| Capricor Therapeutics, Inc. | -23 Million USD | 954.458% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 505.557% |
| GeoVax Labs, Inc. | -26.66 Million USD | 837.199% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 165.629% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 635.272% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -734.013% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -3903.906% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 705.264% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 224.114% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 128.73% |
| Evaxion Biotech A/S | -21.4 Million USD | 1018.572% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 396.02% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 190.322% |
| Trevena, Inc. | -35.28 Million USD | 657.136% |
| Surrozen, Inc. | -41.13 Million USD | 577.99% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 347.012% |
| Cingulate Inc. | -22.95 Million USD | 956.578% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 2735.062% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 627.323% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 2489.9% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 292.246% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 389.858% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 436.809% |
| Clearmind Medicine Inc. | -8.71 Million USD | 2357.027% |
| Kronos Bio, Inc. | -121.83 Million USD | 261.374% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 364.456% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 8152.792% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 294.989% |
| Statera Biopharma, Inc. | 38.93 Million USD | -404.95% |
| ImmunityBio, Inc. | -436.18 Million USD | 145.073% |
| Korro Bio, Inc. | -80.9 Million USD | 343.007% |
| Kineta, Inc. | -15.71 Million USD | 1351.126% |
| BioVie Inc. | -31.95 Million USD | 715.339% |
| Codexis, Inc. | -49.28 Million USD | 498.925% |
| Celularity Inc. | -183.94 Million USD | 206.88% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 188.755% |
| Celcuity Inc. | -58.3 Million USD | 437.167% |
| Virax Biolabs Group Limited | -6.6 Million USD | 3074.697% |
| Cibus, Inc. | -314.58 Million USD | 162.496% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 682.818% |
| IN8bio, Inc. | -28.5 Million USD | 789.735% |
| Kodiak Sciences Inc. | -259.02 Million USD | 175.901% |
| Annexon, Inc. | -141.57 Million USD | 238.868% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 274.604% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 406.253% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 803.28% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 185.475% |
| Eyenovia, Inc. | -24.1 Million USD | 915.572% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -339.001% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 60779.63% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 366.384% |
| Arcellx, Inc. | -64.14 Million USD | 406.496% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 536.757% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 259.223% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 736.623% |
| Moolec Science SA | -52.07 Million USD | 477.532% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 480.967% |
| Geron Corporation | -174.78 Million USD | 212.484% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 586.434% |
| Royalty Pharma plc | 1.88 Billion USD | 89.583% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 264.393% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 2208.501% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 1047.902% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 218.378% |
| Humacyte, Inc. | -96.45 Million USD | 303.821% |
| Structure Therapeutics Inc. | -102.45 Million USD | 291.884% |
| 89bio, Inc. | -134.46 Million USD | 246.213% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 349.258% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -4751.974% |
| Genelux Corporation | -24.16 Million USD | 913.582% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 681.663% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 220.272% |
| Notable Labs, Ltd. | -14.4 Million USD | 1465.292% |
| Liquidia Corporation | -70.05 Million USD | 380.656% |
| Mustang Bio, Inc. | -48.06 Million USD | 509.051% |
| Immunovant, Inc. | -269.97 Million USD | 172.821% |
| Quantum-Si incorporated | -91.8 Million USD | 314.154% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 376.959% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 1118.241% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 292.724% |
| Acasti Pharma Inc. | -11.3 Million USD | 1839.687% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 983.476% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 1382.39% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 193.392% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 4703.892% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 1338.048% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 783.215% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 630.926% |
| PepGen Inc. | -83.58 Million USD | 335.221% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 766.357% |
| United Therapeutics Corporation | 1.38 Billion USD | 85.823% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 958.637% |
| Solid Biosciences Inc. | -93.43 Million USD | 310.418% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 4220.136% |
| Immuneering Corporation | -58.06 Million USD | 438.614% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -6130302.245% |
| Silo Pharma, Inc. | -3.62 Million USD | 5521.688% |
| Belite Bio, Inc | -31.52 Million USD | 723.559% |
| XOMA Corporation | -39.36 Million USD | 599.472% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 391.491% |
| Bionomics Limited | -9.83 Million USD | 2098.598% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 334.092% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 668.115% |
| uniQure N.V. | -253.1 Million USD | 177.678% |
| Cassava Sciences, Inc. | -95.68 Million USD | 305.464% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 2789.458% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 251.812% |
| Forte Biosciences, Inc. | -32.47 Million USD | 705.358% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 2542.117% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 796.701% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 60779.63% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 1864.671% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 1336.413% |
| Altimmune, Inc. | -87.93 Million USD | 323.577% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 313.514% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 668.115% |
| Compugen Ltd. | -12.51 Million USD | 1670.805% |
| Peak Bio, Inc. | -1356.23 USD | 14496313.769% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 504.548% |
| Benitec Biopharma Inc. | -22.49 Million USD | 974.175% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 181.139% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 788.792% |
| Zura Bio Limited | -60.56 Million USD | 424.624% |
| PolyPid Ltd. | -20.26 Million USD | 1070.251% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 1359.22% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 788.792% |
| Instil Bio, Inc. | -146.12 Million USD | 234.546% |
| argenx SE | -216.02 Million USD | 191.01% |
| Immunome, Inc. | -28.27 Million USD | 795.419% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 505.591% |
| Verona Pharma plc | -52.46 Million USD | 474.711% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 307.447% |
| Shattuck Labs, Inc. | -87.61 Million USD | 324.393% |
| CervoMed Inc. | -2.17 Million USD | 9152.183% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 260.828% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 1648.901% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 508.108% |
| Moolec Science SA | -52.07 Million USD | 477.532% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 1247.037% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 250.779% |
| AnaptysBio, Inc. | -143.16 Million USD | 237.326% |
| Design Therapeutics, Inc. | -66.32 Million USD | 396.422% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 342.757% |
| NeurAxis, Inc. | -6.66 Million USD | 3049.991% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 620.8% |
| Lumos Pharma, Inc. | -36.57 Million USD | 637.605% |
| Achilles Therapeutics plc | -70.44 Million USD | 379.098% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 307.447% |
| 180 Life Sciences Corp. | -22.13 Million USD | 988.234% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -3272.683% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 8152.792% |
| Nutriband Inc. | -5.12 Million USD | 3938.551% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 279.139% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 454.672% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 488.926% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 401.181% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 463.338% |
| Palisade Bio, Inc. | -12.28 Million USD | 1700.863% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 533.273% |
| Beam Therapeutics Inc. | -156.47 Million USD | 225.646% |
| Neurogene Inc. | -52.28 Million USD | 476.013% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 244.041% |
| AEON Biopharma, Inc. | -48.36 Million USD | 506.53% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 311.359% |
| Sesen Bio, Inc. | -50.84 Million USD | 486.707% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 339.958% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 1691.916% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 145.996% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 286.889% |
| Athira Pharma, Inc. | -116.7 Million USD | 268.464% |
| Vaccinex, Inc. | -19.74 Million USD | 1095.554% |
| HCW Biologics Inc. | -23.57 Million USD | 933.905% |
| XOMA Corporation | -39.36 Million USD | 599.472% |
| Nektar Therapeutics | -243.1 Million USD | 180.871% |
| Arvinas, Inc. | -394.8 Million USD | 149.798% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -104084.287% |
| Merus N.V. | -149.2 Million USD | 231.765% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 310.292% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 728.925% |
| Rezolute, Inc. | -68.42 Million USD | 387.333% |
| Clene Inc. | -43.24 Million USD | 554.666% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1374.799% |
| BeyondSpring Inc. | -21.54 Million USD | 1012.73% |
| Synlogic, Inc. | -55.16 Million USD | 456.415% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 1727.096% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 1947.416% |
| Peak Bio, Inc. | -1356.23 USD | 14496313.769% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 705.581% |
| Krystal Biotech, Inc. | 17.9 Million USD | -998.09% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 266.017% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 157.596% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 4367.989% |
| MannKind Corporation | 15.12 Million USD | -1199.504% |
| Ikena Oncology, Inc. | -74.39 Million USD | 364.261% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 1661.201% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -867.196% |
| Gossamer Bio, Inc. | -172.15 Million USD | 214.203% |
| CohBar, Inc. | -12.06 Million USD | 1729.421% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 870.716% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 754.794% |
| Legend Biotech Corporation | -477.87 Million USD | 141.141% |
| Mural Oncology plc | -192.72 Million USD | 202.014% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 272.376% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 1317.706% |
| Disc Medicine, Inc. | -91.02 Million USD | 315.987% |
| Champions Oncology, Inc. | -5.05 Million USD | 3990.028% |
| REGENXBIO Inc. | -239.46 Million USD | 182.101% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 1934.284% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 452.611% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 607.121% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 274.283% |
| Vaxart, Inc. | -74.72 Million USD | 363.108% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 658.397% |
| Cellectis S.A. | -98.09 Million USD | 300.42% |
| Longeveron Inc. | -20.06 Million USD | 1080.07% |
| Repare Therapeutics Inc. | -114.27 Million USD | 272.046% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 144.764% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 362.795% |
| Revolution Medicines, Inc. | -430.58 Million USD | 145.66% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 3226.125% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 738.546% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 363.577% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -3909.831% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 1892.996% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 95.731% |
| Denali Therapeutics Inc. | -179.97 Million USD | 209.24% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 206597.353% |
| Veru Inc. | -89.97 Million USD | 318.506% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 831.461% |
| Cingulate Inc. | -22.95 Million USD | 956.578% |
| Passage Bio, Inc. | -98.34 Million USD | 299.919% |
| Context Therapeutics Inc. | -25.06 Million USD | 884.507% |
| Exicure, Inc. | -15.53 Million USD | 1365.217% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 195.408% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 631.702% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 3397.255% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 216.703% |
| Nuvalent, Inc. | -149.49 Million USD | 231.513% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 2517.511% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 328.889% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 751.475% |
| OmniAb, Inc. | -49.73 Million USD | 495.331% |
| Anew Medical, Inc. | -1.3 Million USD | 15213.465% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 1690.116% |
| Lipocine Inc. | -16.32 Million USD | 1304.472% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 394.888% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 364.595% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 615.566% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 603.927% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 986.273% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 136.069% |
| Ocugen, Inc. | -64.82 Million USD | 403.272% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 312.382% |
| Q32 Bio Inc. | -86.5 Million USD | 327.28% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 1261.47% |
| Alumis Inc. Common Stock | -156.89 Million USD | 225.312% |
| Equillium, Inc. | -12.13 Million USD | 1719.723% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 436.233% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 2587.578% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1142.375% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 521.061% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 284.872% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 1199.159% |
| Dominari Holdings Inc. | -22.44 Million USD | 976.123% |
| Edesa Biotech, Inc. | -8.19 Million USD | 2500.471% |
| vTv Therapeutics Inc. | -25.41 Million USD | 873.658% |
| Bio-Techne Corporation | 326.66 Million USD | 39.815% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 151.083% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 9.144% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 249.954% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 625.238% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 230.113% |
| Nkarta, Inc. | -120.48 Million USD | 263.181% |
| BioCardia, Inc. | -11.56 Million USD | 1800.709% |
| Iterum Therapeutics plc | -34.58 Million USD | 668.543% |